CovidChloroV1, Main, Corpus, bibRecord, 001006

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.

Identifieur interne : 001006 ( Main/Corpus ); précédent : 001005; suivant : 001007

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.

Auteurs : Li Zou ; Lijun Dai ; Xingyu Zhang ; Zhaohui Zhang ; Zhentao Zhang

Source :

Archives of pharmacal research [ 0253-6269 ] ; 2020.

RBID : pubmed:32740801

English descriptors

KwdEn :
- Antimalarials (MeSH), COVID-19 (MeSH), Chloroquine (therapeutic use), Coronavirus Infections (drug therapy), Humans (MeSH), Hydroxychloroquine (therapeutic use), Pandemics (MeSH), Pneumonia, Viral (drug therapy).
MESH :
- chemical , therapeutic use : Chloroquine, Hydroxychloroquine.
- chemical : Antimalarials.
- drug therapy : Coronavirus Infections, Pneumonia, Viral.
- COVID-19, Humans, Pandemics.

Abstract

A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.

DOI: 10.1007/s12272-020-01258-7
PubMed: 32740801
PubMed Central: PMC7395211

Links to Exploration step

pubmed:32740801

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.</title>
<author><name sortKey="Zou, Li" sort="Zou, Li" uniqKey="Zou L" first="Li" last="Zou">Li Zou</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dai, Lijun" sort="Dai, Lijun" uniqKey="Dai L" first="Lijun" last="Dai">Lijun Dai</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Xingyu" sort="Zhang, Xingyu" uniqKey="Zhang X" first="Xingyu" last="Zhang">Xingyu Zhang</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Zhaohui" sort="Zhang, Zhaohui" uniqKey="Zhang Z" first="Zhaohui" last="Zhang">Zhaohui Zhang</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhzhqing1990@163.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Zhentao" sort="Zhang, Zhentao" uniqKey="Zhang Z" first="Zhentao" last="Zhang">Zhentao Zhang</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhentaozhang@whu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32740801</idno>
<idno type="pmid">32740801</idno>
<idno type="doi">10.1007/s12272-020-01258-7</idno>
<idno type="pmc">PMC7395211</idno>
<idno type="wicri:Area/Main/Corpus">001006</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">001006</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.</title>
<author><name sortKey="Zou, Li" sort="Zou, Li" uniqKey="Zou L" first="Li" last="Zou">Li Zou</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Dai, Lijun" sort="Dai, Lijun" uniqKey="Dai L" first="Lijun" last="Dai">Lijun Dai</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Xingyu" sort="Zhang, Xingyu" uniqKey="Zhang X" first="Xingyu" last="Zhang">Xingyu Zhang</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Zhaohui" sort="Zhang, Zhaohui" uniqKey="Zhang Z" first="Zhaohui" last="Zhang">Zhaohui Zhang</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhzhqing1990@163.com.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Zhang, Zhentao" sort="Zhang, Zhentao" uniqKey="Zhang Z" first="Zhentao" last="Zhang">Zhentao Zhang</name>
<affiliation><nlm:affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhentaozhang@whu.edu.cn.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Archives of pharmacal research</title>
<idno type="ISSN">0253-6269</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (MeSH)</term>
<term>COVID-19 (MeSH)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Chloroquine</term>
<term>Hydroxychloroquine</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Antimalarials</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>Pneumonia, Viral</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Humans</term>
<term>Pandemics</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32740801</PMID>
<DateCompleted><Year>2020</Year>
<Month>09</Month>
<Day>03</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>12</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0253-6269</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>43</Volume>
<Issue>8</Issue>
<PubDate><Year>2020</Year>
<Month>Aug</Month>
</PubDate>
</JournalIssue>
<Title>Archives of pharmacal research</Title>
<ISOAbbreviation>Arch Pharm Res</ISOAbbreviation>
</Journal>
<ArticleTitle>Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.</ArticleTitle>
<Pagination><MedlinePgn>765-772</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s12272-020-01258-7</ELocationID>
<Abstract><AbstractText>A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zou</LastName>
<ForeName>Li</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Dai</LastName>
<ForeName>Lijun</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Xingyu</ForeName>
<Initials>X</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Zhaohui</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhzhqing1990@163.com.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Zhang</LastName>
<ForeName>Zhentao</ForeName>
<Initials>Z</Initials>
<AffiliationInfo><Affiliation>Department of Neurology, Renmin Hospital of Wuhan University, Wuhan, 430060, China. zhentaozhang@whu.edu.cn.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>81822016</GrantID>
<Agency>National Natural Science Foundation of China</Agency>
<Country></Country>
</Grant>
<Grant><GrantID>81771382</GrantID>
<Agency>National Natural Science Foundation of China</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>08</Month>
<Day>01</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Korea (South)</Country>
<MedlineTA>Arch Pharm Res</MedlineTA>
<NlmUniqueID>8000036</NlmUniqueID>
<ISSNLinking>0253-6269</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName>
</SupplMeshList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Chloroquine</Keyword>
<Keyword MajorTopicYN="N">Hydroxychloroquine</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">Treatment</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>05</Month>
<Day>06</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>07</Month>
<Day>26</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>9</Month>
<Day>4</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>8</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32740801</ArticleId>
<ArticleId IdType="doi">10.1007/s12272-020-01258-7</ArticleId>
<ArticleId IdType="pii">10.1007/s12272-020-01258-7</ArticleId>
<ArticleId IdType="pmc">PMC7395211</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Gen Virol. 1983 May;64(Pt 5):1149-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6842189</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurotox Res. 2018 Jul;34(1):62-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29285614</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Gen Virol. 1969 Mar;4(2):203-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">4306296</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Mal Infect. 2020 Jun;50(4):384</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32240719</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Glob Health. 2020 May;8(5):e639-e640</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32199468</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Glob J Health Sci. 2015 Jun 25;8(3):59-64</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26493438</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lupus. 1996 Jun;5 Suppl 1:S11-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8803904</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Antimicrob Chemother. 2015;70(6):1608-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25693996</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drug Saf. 2018 Oct;41(10):919-931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29858838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Retrovirology. 2007 Jan 30;4:6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17263871</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Br J Clin Pharmacol. 1983 Apr;15(4):502-3</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6849790</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mil Med Res. 2020 Mar 13;7(1):11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32169119</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Can J Cardiol. 2014 Dec;30(12):1706-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25475472</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020 May 25;49(2):215-219</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32391667</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Pharmacokinet. 1996 Oct;31(4):257-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8896943</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 1990 Feb;174(2):450-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2154882</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2020 Mar;30(3):269-271</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32020029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2018 Jan;149:143-149</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29175128</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2020 May;177:104762</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32147496</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Toxicol (Phila). 2006;44(2):173-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16615675</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Travel Med Infect Dis. 2020 Mar - Apr;34:101663</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32289548</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Intervirology. 1998;41(6):261-71</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10325536</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Inorg Biochem. 2003 Feb 1;94(1-2):36-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12620671</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Intern Med. 2020 Mar 13;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32167524</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Feb;23(2):300-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23208422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 Mar 18;6:16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32194981</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Feb 7;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32031570</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antimicrob Agents Chemother. 2009 Aug;53(8):3416-21</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19506054</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ophthalmology. 2016 Jun;123(6):1386-94</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26992838</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Infect Dis Poverty. 2020 Mar 17;9(1):29</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32183901</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Drug Investig. 2018 Aug;38(8):653-671</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29737455</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>EBioMedicine. 2017 Oct;24:189-194</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29033372</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Acta Trop. 2002 Jul;83(1):49-61</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12062793</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Immunopharmacol Immunotoxicol. 2013 Jun;35(3):434-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23635029</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Allergy. 2020 Jul;75(7):1730-1741</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Crit Care. 2020 Jun;57:279-283</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32173110</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 Jul;56(1):105949</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32205204</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Rheumatol. 2017 Mar;44(3):398</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28250164</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001006 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 001006 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32740801
   |texte=   Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i   -Sk "pubmed:32740801" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.

Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki